Latest Headlines from Nourish | The Nourish Mission

Measles Fight Extends Beyond Vaccines

What's happened

Health officials report rising measles cases and warn that vaccines alone may not suffice. Biotech firms are developing short-term monoclonal antibody therapies to protect high-risk groups while public health efforts press to boost vaccination rates.

What's behind the headline?

Insightful take

  • Measles outbreaks are driving interest in therapeutic countermeasures, not just vaccines.
  • Monoclonal antibodies could offer temporary protection for high-risk populations during outbreaks.
  • The timeline remains long, with trials and regulatory approvals likely years away.

What’s changing

  • A shift from vaccine-only reliance to combining vaccines with targeted therapies for rapid, short-term protection.

What readers should watch

  • If a local outbreak occurs, healthcare providers may consider monoclonal antibodies for high-risk individuals, pending FDA sign-off.

How we got here

Public health officials have faced a resurgence of measles as vaccination rates dip. Experts warn that outbreaks, while currently concentrated in a few U.S. communities, threaten broader vulnerability, especially among infants and immunocompromised individuals. Biotech companies are pursuing monoclonal antibodies as a potential stopgap.

Our analysis

- Ars Technica (Emily Mullin) reports on Invivyd’s monoclonal antibody work for measles and the broader context of vaccination gaps in the U.S. - The New York Times notes ongoing measles case counts and the political hurdles to reversing Hesitancy, while The Conversation discusses vaccine hesitancy histories. - The Conversation discusses historical vaccine skepticism and storytelling strategies used by vaccine-hesitant groups. - These sources show a landscape where vaccines remain central but therapies are being explored as supplements in outbreaks.

Go deeper

  • Will monoclonal antibodies become standard during outbreaks or stay experimental?
  • How should communities balance vaccine campaigns with new therapies?
  • What timelines are realistic for approval and deployment?

More on these topics


Latest Headlines from Nourish | The Nourish Mission